The ATM protein kinase and cellular redox signaling: Beyond the DNA damage response

Trends in Biochemical Sciences

Volumn 37, Issue 1, 2012, Pages 15-22

  Ditch, Scott ^a   Paull, Tanya T ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; METFORMIN; PROTEIN P53;

CARBOXY TERMINAL SEQUENCE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; ELECTRON TRANSPORT; GENE LOCUS; GENETIC VARIABILITY; GLUCOSE TRANSPORT; GLUTATHIONE METABOLISM; HOMOLOGOUS RECOMBINATION; HUMAN; INSULIN RESISTANCE; MISSENSE MUTATION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PURKINJE CELL; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; GLUTATHIONE; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MAMMALIA;

EID: 84855607470     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.10.002     Document Type: Review

References (97)

1. Zhang N., et al. Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8021-8026.
2. Lavin M.F., et al. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br. Med. Bull. 2007, 81-82:129-147.
3. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. (Berl.) 2004, 82:510-529.
4. Bredemeyer A.L., et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 2006, 442:466-470.
5. Lempiainen H., Halazonetis T.D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28:3067-3073.
6. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40:179-204.
7. Falck J., et al. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
8. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9:616-627.
9. Mahaney B.L., et al. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem. J. 2009, 417:639-650.
10. Lee J.H., Paull T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007, 26:7741-7748.
11. You Z., et al. CtIP links DNA double-strand break sensing to resection. Mol. Cell 2009, 36:954-969.
12. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
13. Lee J.H., Paull T.T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 2004, 304:93-96.
14. Lee J.H., Paull T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308:551-554.
15. Uziel T., et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 2003, 22:5612-5621.
16. Lavin M.F. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 2008, 9:759-769.
17. Matsuoka S., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
18. Barlow C., et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat. Genet. 1997, 17:453-456.
19. Matsuoka S., et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10389-10394.
20. Banin S., et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
21. Bartkova J., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
22. Canman C.E., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998, 281:1677-1679.
23. Zhan H., et al. Ataxia telangiectasia mutated (ATM)-mediated DNA damage response in oxidative stress-induced vascular endothelial cell senescence. J. Biol. Chem. 2010, 285:29662-29670.
24. Bensimon A., et al. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. Sci. Signal. 2010, 3:rs3.
25. Bensimon A., et al. Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett. 2011, 585:1625-1639.
26. Lavin M.F., Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 1997, 15:177-202.
27. Goodarzi A.A., et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol. Cell 2008, 31:167-177.
28. Lim D.S., et al. ATM binds to beta-adaptin in cytoplasmic vesicles. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10146-10151.
29. Watters D., et al. Localization of a portion of extranuclear ATM to peroxisomes. J. Biol. Chem. 1999, 274:34277-34282.
30. Barlow C., et al. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:871-876.
31. Boehrs J.K., et al. Constitutive expression and cytoplasmic compartmentalization of ATM protein in differentiated human neuron-like SH-SY5Y cells. J. Neurochem. 2007, 100:337-345.
32. Li J., et al. Cytoplasmic ATM in neurons modulates synaptic function. Curr. Biol. 2009, 19:2091-2096.
33. Barzilai A., et al. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst.) 2002, 1:3-25.
34. Meredith M.J., Dodson M.L. Impaired glutathione biosynthesis in cultured human ataxia-telangiectasia cells. Cancer Res. 1987, 47:4576-4581.
35. Yi M., et al. Response of fibroblast cultures from ataxia-telangiectasia patients to oxidative stress. Cancer Lett. 1990, 54:43-50.
36. Ward A.J., et al. Response of fibroblast cultures from ataxia-telangiectasia patients to reactive oxygen species generated during inflammatory reactions. Environ. Mol. Mutagen. 1994, 24:103-111.
37. Shackelford R.E., et al. The Ataxia telangiectasia gene product is required for oxidative stress-induced G1 and G2 checkpoint function in human fibroblasts. J. Biol. Chem. 2001, 276:21951-21959.
38. Kamsler A., et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res. 2001, 61:1849-1854.
39. Quick K.L., Dugan L.L. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann. Neurol. 2001, 49:627-635.
40. Ito K., et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004, 431:997-1002.
41. Kim J., Wong P.K. Oxidative stress is linked to ERK1/2-p16 signaling-mediated growth defect in ATM-deficient astrocytes. J. Biol. Chem. 2009, 284:14396-14404.
42. Kurz E.U., et al. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 2004, 279:53272-53281.
43. Guo Z., et al. ATM activation by oxidative stress. Science 2010, 330:517-521.
44. Guo Z., et al. ATM activation in the presence of oxidative stress. Cell Cycle 2010, 9:4805-4811.
45. Chessa L., et al. Heterogeneity in ataxia-telangiectasia: classical phenotype associated with intermediate cellular radiosensitivity. Am. J. Med. Genet. 1992, 42:741-746.
46. Gilad S., et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am. J. Hum. Genet. 1998, 62:551-561.
47. Toyoshima M., et al. Ataxia-telangiectasia without immunodeficiency: novel point mutations within and adjacent to the phosphatidylinositol 3-kinase-like domain. Am. J. Med. Genet. 1998, 75:141-144.
48. Kern J.K., Jones A.M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J. Toxicol. Environ. Health B: Crit. Rev. 2006, 9:485-499.
49. Rass U., et al. Defective DNA repair and neurodegenerative disease. Cell 2007, 130:991-1004.
50. Bar R.S., et al. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N. Engl. J. Med. 1978, 298:1164-1171.
51. Schalch D.S., et al. An unusual form of diabetes mellitus in ataxia telangiectasia. N. Engl. J. Med. 1970, 282:1396-1402.
52. Peretz S., et al. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1676-1681.
53. Viniegra J.G., et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 2005, 280:4029-4036.
54. Halaby M.J., et al. ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal. 2008, 20:1555-1563.
55. Li Y., Yang D.Q. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol. Cancer Ther. 2010, 9:113-125.
56. Armata H.L., et al. Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol. Cell Biol. 2010, 30:5787-5794.
57. Sablina A.A., et al. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11:1306-1313.
58. Roberts C.K., Sindhu K.K. Oxidative stress and metabolic syndrome. Life Sci. 2009, 84:705-712.
59. Yang D.Q., Kastan M.B. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat. Cell Biol. 2000, 2:893-898.
60. Baker R.G., et al. NF-kappaB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
61. Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Res. 2011, 21:116-130.
62. Alexander A., et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4153-4158.
63. Sun Y., et al. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol. Cell Biochem. 2007, 306:239-245.
64. Suzuki A., et al. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem. Biophys. Res. Commun. 2004, 324:986-992.
65. Hardie D.G., Hawley S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 2001, 23:1112-1119.
66. Shaw R.J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. (Oxf.) 2009, 196:65-80.
67. -/- mice. Biochem. Biophys. Res. Commun. 2009, 383:368-372.
68. Sengupta S., et al. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.
69. Schieke S.M., et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006, 281:27643-27652.
70. Dann S.G., et al. mTOR complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 2007, 13:252-259.
71. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl. 2):S43-S51.
72. Zhou K., et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 2011, 43:117-120.
73. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
74. Vazquez-Martin A., et al. Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 2011, 10:1499-1501.
75. Owen M.R., et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348:607-614.
76. Ambrose M., et al. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum. Mol. Genet. 2007, 16:2154-2164.
77. Patel A.Y., et al. Ataxia telangiectasia mutated influences cytochrome c oxidase activity. Biochem. Biophys. Res. Commun. 2011, 405:599-603.
78. Cosentino C., et al. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 2011, 30:546-555.
79. Vaughn A.E., Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol. 2008, 10:1477-1483.
80. Bencokova Z., et al. ATM activation and signaling under hypoxic conditions. Mol. Cell Biol. 2009, 29:526-537.
81. 2 sensing. J. Biol. Chem. 2000, 275:25130-25138.
82. Cam H., et al. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol. Cell 2010, 40:509-520.
83. Majmundar A.J., et al. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40:294-309.
84. DeYoung M.P., et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22:239-251.
85. Li M., et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14188-14193.
86. Zha S., et al. Complementary functions of ATM and H2AX in development and suppression of genomic instability. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9302-9306.
87. Kozlov S.V., et al. Involvement of novel autophosphorylation sites in ATM activation. EMBO J. 2006, 25:3504-3514.
88. Perry J., Kleckner N. The ATRs, ATMs, and TORs are giant HEAT repeat proteins. Cell 2003, 112:151-155.
89. Shahrabani-Gargir L., et al. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004, 145:5679-5687.
90. Fraser M., et al. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011, 10:2218-2232.
91. Khalil A., et al. ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 2011, 10:481-491.
92. Hussain S.P., et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res. 2004, 64:2350-2356.
93. Cunningham J.T., et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
94. Kozlov S.V., et al. Autophosphorylation and ATM activation: additional sites add to the complexity. J. Biol. Chem. 2010, 286:9107-9119.
95. Daniel J.A., et al. Multiple autophosphorylation sites are dispensable for murine ATM activation in vivo. J. Cell Biol. 2008, 183:777-783.
96. Pellegrini M., et al. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 2006, 443:222-225.
97. So S., et al. Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J. Cell Biol. 2009, 187:977-990.